Sterile inflammation in LHON: mitochondrial stress, innate immune signaling, and implications for AAV gene therapy
Authors:
Open Access
- 18 September 2026
- journal article
- review article
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 17, 1935135
Abstract
Leber hereditary optic neuropathy (LHON) is a mitochondrial disease caused primarily by pathogenic mitochondrial DNA (mtDNA) variants that impair respiratory chain complex I function. Although bioenergetic failure, oxidative stress, and retinal ganglion cell degeneration are central features of disease pathogenesis, these mechanisms do not fully explain the incomplete penetrance, male predominance, and marked clinical heterogeneity observed in LHON. Emerging evidence suggests that mitochondrial dysfunction can also trigger sterile inflammatory responses through the release of mitochondrial damage-associated molecular patterns (DAMPs), including mtDNA and reactive oxygen species, and through impaired mitophagic clearance. These signals activate innate immune pathways, including cGAS-STING, TLR9, and the NLRP3 inflammasome, potentially contributing to neuroinflammation, glial activation, and secondary neuronal injury. The relevance of immune signaling has gained further attention with the development of AAV-based gene therapies for LHON, where treatment-associated ocular inflammation has emerged as a clinically important challenge. In this review, we examine the evidence linking mitochondrial dysfunction to innate immune activation in LHON, discuss the immunological mechanisms underlying disease progression and gene therapy-associated inflammation, and highlight emerging opportunities for biomarker development, immunomodulatory intervention, and improved therapeutic design. We propose that LHON should be viewed not only as a disorder of mitochondrial bioenergetics but also as a neuroinflammatory disease shaped by the interplay between mitochondrial stress and immune signaling.Keywords
This publication has 119 references indexed in Scilit:
- Five-Year Outcomes of Lenadogene Nolparvovec Gene Therapy in Leber Hereditary Optic NeuropathyJAMA Ophthalmology, 2025
- Evaluating the Evidence for Neuroprotective and Axonal Regenerative Activities of Different Inflammatory Cell Types After Optic Nerve InjuryMolecular Neurobiology, 2024
- Safety of Intravitreal Gene Therapy for Treatment of Subjects with Leber Hereditary Optic Neuropathy due to Mutations in the Mitochondrial ND4 Gene: The REVEAL StudyBioDrugs, 2021
- Immune Response and Intraocular Inflammation in Patients With Leber Hereditary Optic Neuropathy Treated With Intravitreal Injection of Recombinant Adeno-Associated Virus 2 Carrying the ND4 GeneJAMA Ophthalmology, 2019
- Trial End Points and Natural History in Patients With G11778A Leber Hereditary Optic NeuropathyJAMA Ophthalmology, 2014
- Minocycline Delays Death of Retinal Ganglion Cells in Experimental Glaucoma and After Optic Nerve TransectionArchives of Ophthalmology (1950), 2006
- Mitochondrial mutations of Leber's hereditary optic neuropathy: a risk factor for multiple sclerosisJournal of Neurology, 2000
- A Histopathologic and Morphometric Differentiation of Nerves in Optic Nerve Hypoplasia and Leber Hereditary Optic NeuropathyArchives of Ophthalmology (1950), 1998
- HLA class I genotypes in Leber's hereditary optic neuropathyJournal of the Neurological Sciences, 1996
- HLA class II genotypes in Leber's hereditary optic neuropathyJournal of the Neurological Sciences, 1994